Pacira BioSciences Inc 2026年季度报告

FORM10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF1934 For the Quarterly Period Ended March31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF1934 For the transition period fromtoCommission File Number: 001-35060 PACIRA BIOSCIENCES,INC. (Exact Name of Registrant as Specified in its Charter) (I.R.S. EmployerIdentification No.) 2000 Sierra Point Parkway, Suite 900Brisbane, California 94005(Address and Zip Code of Principal Executive Offices)(650) 242-8052(Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registered Nasdaq Global Select Market Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that theregistrant was required to submit such files.)☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).☐Yes☒NoAs of April29, 2026, 39,347,924 shares of the registrant’s common stock, $0.001 par value per share, were outstanding. PACIRA BIOSCIENCES,INC.QUARTERLY REPORT ON FORM 10-QFOR THE QUARTER ENDED MARCH 31, 2026 TABLE OF CONTENTS Item1.Financial Statements (Unaudited)2Condensed Consolidated Balance Sheets2Condensed Consolidated Statements of Operations3Condensed Consolidated Statements of Comprehensive Income4Condensed Consolidated Statements of Stockholders’ Equity5Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements7Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations30Item3.Quantitative and Qualitative Disclosures About Market Risk46Item4.Controls and Procedures46 Item1.Legal Proceedings48Item1A.Risk Factors48Item2.Unregistered Sales of Equity Securities and Use of Proceeds48Item3.Defaults Upon Senior Securities48Item4.Mine Safety Disclosures48Item5.Other Information49Item6.Exhibits49Signatures50 Pacira BioSciences, Inc. | Q12026Quarterly Report on Form 10-Q | 1 Table of Contents PARTI — FINANCIAL INFORMATIONItem1.FINANCIAL STATEMENTS (Unaudited) PACIRA BIOSCIENCES,INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except share and per share amounts)(Unaudited) PACIRA BIOSCIENCES,INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(Unaudited) PACIRA BIOSCIENCES,INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(In thousands)(Unaudited) See accompanying notes to condensed consolidated financial statements. Pacira BioSciences, Inc. | Q12026Quarterly Report on Form 10-Q | 4 PACIRA BIOSCIENCES,INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITYFOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025(In thousands)(Unaudited) Pacira BioSciences, Inc. | Q12026Quarterly Report on Form 10-Q | 5 Pacira BioSciences, Inc. | Q12026Quarterly Report on Form 10-Q | 6 PACIRA BIOSCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) NOTE 1—DESCRIPTION OF BUSINESS Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) deliver innovative, non-opioid paintherapies to transform the lives of patients. The Company’s long-acting, local analgesic, EXPAREL(bupivacaine liposome injectablesuspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and theUnited Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome, or pMVL, drugdelivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time.EXPAREL is currently indicated to produce postsurgical local analgesia via i